ArticleScientific reports2025
Identify the co-expressed genes of hypertensive nephropathy and diabetic nephropathy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- USF1 transcriptionally activates TRIM55 to promote diabetic cardiomyopathy progression by enhancing HSPB1 protein degradation.Journal of bioenergetics and biomembranes · 2026Article
- Identification and dual-center histological validation of EMT core genes in chronic rhinosinusitis with nasal polyps: an integrated multi-cohort transcriptomic and single-cell analysis.Frontiers in immunology · 2026Article
- Machine Learning Models for Identifying the Risk of Chronic Kidney Disease in Patients with Coronary Heart Disease: A Retrospective Study.International journal of general medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study focused on the intricate connections between hypertension nephropathy (HN) and diabetic nephropathy (DN) in terms of molecular and pathological mechanisms. The samples were from the Gene Expression Omnibus (GEO) database. GSE37460 and GSE142153 are training sets, and GSE37455 and GSE30529 are validation sets. We found 42 shared differentially expressed genes (DEGs) by means of the differential analysis. The GO/KEGG and GSEA analysis mainly highlights the signal transduction pathways related to the proteasome and cytokines. The eight hub genes identified through the Protein-Protein Interaction (PPI) network analysis include NR4A1, TNFSF10, CX3CR1, EGF, THBD, CXCR4, CCL5, and ATF3. Single-cell sequencing analysis revealed that TNFSF10 and NR4A1 were the most highly expressed in the cells of both HN and DN. Furthermore, five significant microRNAs identified include hsa-miR-1248, hsa-miR-200b-5p, hsa-miR-23b-5p, hsa-miR-3059-5p, and hsa-miR-3065-3p. Six essential transcription factors (TFs) (NFIL3, STAT3, NFKB1, USF1, USF2, and EGR1), 11 important drug chemicals (Cisplatin, Cyclosporine, perfluorooctanoic acid, Quercetin, Tretinoin, bisphenol A, Curcumin, Valproic Acid, Particulate Matter, Simvastatin, and Cadmium), seven related diseases (Atherosclerosis, Glioblastoma, Pulmonary Fibrosis, Asthma, Hepatitis B, Hepatitis C, and Diabetes Mellitus), and ten important RNA-binding proteins (RBPs) (CHTOP, EIF4E, HNRNPK, IGF2BP3, YTHDF3, HNRNPA2B1, RBM47, YBX1, RBFOX2, and RBM10). Finally, molecular docking simulations suggest that Tretinoin and Curcumin may have potential therapeutic value for both HN and DN. This study provides novel therapeutic targets for the combined diagnosis and treatment of HN and DN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.